Using blood tests to manage gastrointestinal tumors

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study evaluates the role of circulating tumor DNA (ctDNA) in managing patients with gastrointestinal tumors, including pancreatic, colon, and biliary tract cancers. Conducted at a single center, it involves collecting blood and fecal samples from patients at specific time points to analyze ctDNA as a biomarker. The aim is to enhance diagnostic and therapeutic strategies for these cancers while ensuring patient anonymity and data protection.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Age \>18 years
* PS ECOG \<2;
* Histological diagnosis of gastrointestinal cancer: esophageal, gastric, intestinal, pancreatic, biliary tract neoplasms;
* Radiological evidence of resectable/locally advanced/metastatic disease on the date of signing the written informed consent;
* Adequate organ and function;
* Availability of tumor histological material.

Exclusion Criteria:

* No histological diagnosis of neoplasia of the gastrointestinal tract.
* No written informed consent.

Where it's running

• Policlinico Agostino Gemelli
  Rome, Lazio, Italy Recruiting

Study contacts

• Principal investigator: Lisa Sakvatore, MD, PhD — Fondazione Policlinico Universitario Agostino Gemelli IRCCS
• Study coordinator: Lisa Salvatore, MD, PhD
• Email: lisa.salvatore@policlinicogemelli.it
• Phone: +390630156318

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Using virtual reality to help manage pain in GI cancer patients

  This study is testing if virtual reality can help people with GI cancer manage their severe abdominal pain better than standard treatments.

  Recruiting Cedars-Sinai Medical Center · Los Angeles, California · NCT04907643

• Cutting down ultra-processed foods for people at high cancer risk

  This project tests whether using the Open Food Facts smartphone app alongside nutrition education helps adults at high risk of cancer eat fewer ultra-processed foods.

  Recruiting at 2 sites Gustave Roussy, Cancer Campus, Grand Paris · Avignon and 2 other locations · NCT07436312

• CEA-targeted CAR-T for advanced CEA-positive solid tumors

  This trial will try CEA-targeted CAR-T cell infusions in adults with advanced CEA-positive cancers (such as colorectal, gastric, esophageal, lung, or pancreatic cancer) to see if the treatment is safe and helps control the disease.

  Recruiting Phase 1 Chongqing Precision Biotech Co., Ltd · Hefei, Anhui · NCT07179692

• Improving care for Black patients with gastrointestinal cancer

  This study is trying to improve cancer care for Black patients with gastrointestinal cancers by ensuring they get the right tests and treatments while helping us understand the challenges they face.

  Recruiting Case Comprehensive Cancer Center · Cleveland, Ohio · NCT06263088

• Testing MDX2001 for advanced solid tumors

  This study is testing a new drug called MDX2001 to see if it can safely help people with advanced solid tumors like breast or colon cancer.

  Recruiting at 6 sites Phase 1/2 ModeX Therapeutics, An OPKO Health Company · Denver, Colorado and 5 other locations · NCT06239194

• Treatment using CEA-targeted CAR-T cells for advanced solid tumors

  This study is testing a new type of immune therapy using CAR-T cells to see if it can help people with advanced solid tumors that have a specific marker called CEA.

  Recruiting Phase 1 Chongqing Precision Biotech Co., Ltd · Wuhu, Anhui · NCT06126406

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.